https://european-biotechnology.net/wp-content/uploads/2025/07/Bayer-Berlin_428625549_nMEd7NyJ7x7YYS941qTmpiKXLUeNZHgC-e1753694788880.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-28 09:27:482025-07-28 09:27:48Bayer targets leading position in HER2-positive NSCLC
https://european-biotechnology.net/wp-content/uploads/2025/07/Curevac_2ndgen-1030x683-1.jpg6831030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-24 06:20:492025-07-24 06:20:49From Brisbane to London to Paris: Vicebio´s Sanofi deal
https://european-biotechnology.net/wp-content/uploads/2025/07/Bildschirmfoto_2022-09-02_um_10.45.28.png167334Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-23 13:52:012025-07-24 07:32:02Abivax soars 500% on TOP-Line data
https://european-biotechnology.net/wp-content/uploads/2025/07/Carbios-Production.png565843Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-22 09:10:552025-07-22 09:10:55Carbios is back with a partnership in the automotive tyre industry
